

# William G Wierda

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5916319/william-g-wierda-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

172  
papers

19,339  
citations

69  
h-index

138  
g-index

180  
ext. papers

22,360  
ext. citations

7  
avg. IF

6.25  
L-index

| #   | Paper   | IF   | Citations |
|-----|---|------|-----------|
| 172 | Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.. <i>Leukemia</i> , <b>2022</b> ,                      | 10.7 | 15        |
| 171 | Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.. <i>Blood</i> , <b>2022</b> ,  | 2.2  | 10        |
| 170 | Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.. <i>Leukemia and Lymphoma</i> , <b>2022</b> , 1-9   | 1.9  | 2         |
| 169 | Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets.. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 43   | 7    | 1         |
| 168 | Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells.. <i>Leukemia</i> , <b>2022</b> ,   | 10.7 | 2         |
| 167 | Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. <i>Blood</i> , <b>2021</b> ,   | 2.2  | 13        |
| 166 | Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3853-3865 | 2.2  | 17        |
| 165 | RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. <i>Leukemia</i> , <b>2021</b> ,   | 10.7 | 1         |
| 164 | The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View. <i>Journal of Experimental Pharmacology</i> , <b>2021</b> , 13, 923-935   | 3    | 4         |
| 163 | Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet, The</i> , <b>2021</b> , 397, 892-901   | 40   | 81        |
| 162 | KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. <i>Blood</i> , <b>2021</b> , 138, 11-22   | 2.2  | 21        |
| 161 | Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. <i>Leukemia</i> , <b>2021</b> , 35, 3282-3286  | 10.7 | 14        |
| 160 | Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (IFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. <i>Leukemia</i> , <b>2021</b> , 35, 3421-3429  | 10.7 | 5         |
| 159 | Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , <b>2021</b> , 194, 61-68   | 4.5  | 1         |
| 158 | Acalabrutinib in treatment-naïve chronic lymphocytic leukemia. <i>Blood</i> , <b>2021</b> , 137, 3327-3338  | 2.2  | 18        |
| 157 | Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. <i>Leukemia</i> , <b>2021</b> , 35, 3059-3072   | 10.7 | 6         |
| 156 | CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. <i>Leukemia</i> , <b>2021</b> , 35, 1610-1620  | 10.7 | 4         |

|     |   |      |     |
|-----|---|------|-----|
| 155 | Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 1129-1135  | 1.9  | 5   |
| 154 | Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1213-1219  | 13.4 | 17  |
| 153 | International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , <b>2020</b> , 135, 1859-1869   | 2.2  | 45  |
| 152 | Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations. <i>Lancet Haematology</i> , <b>2020</b> , 7, e168-e176  | 14.6 | 4   |
| 151 | AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 3856-3867   | 12.9 | 26  |
| 150 | Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 545-553  | 59.2 | 652 |
| 149 | Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. <i>Blood</i> , <b>2020</b> , 135, 1204-1213   | 2.2  | 81  |
| 148 | Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study. <i>Blood</i> , <b>2020</b> , 136, 16-17 | 2.2  | 26  |
| 147 | Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. <i>Blood</i> , <b>2020</b> , 136, 42-43  | 2.2  | 7   |
| 146 | Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. <i>Blood Advances</i> , <b>2020</b> , 4, 4508-4511   | 7.8  | 7   |
| 145 | Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. <i>Lancet, The</i> , <b>2020</b> , 395, 1278-1291                                    | 40   | 201 |
| 144 | Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. <i>Cancer Cell</i> , <b>2019</b> , 36, 369-384.e13   | 24.3 | 107 |
| 143 | Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia. <i>Leukemia</i> , <b>2019</b> , 33, 1663-1674  | 10.7 | 9   |
| 142 | Ibrutinib and Venetoclax for First-Line Treatment of CLL. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 2095-2103   | 59.2 | 256 |
| 141 | Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. <i>Blood</i> , <b>2019</b> , 134, 111-122  | 2.2  | 94  |
| 140 | Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , <b>2019</b> , 133, 2765-2775   | 2.2  | 42  |
| 139 | Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 852-864  | 4.5  | 14  |
| 138 | Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies. <i>Drugs</i> , <b>2019</b> , 79, 1287-1304   | 12.1 | 13  |

|     |  |      |     |
|-----|--|------|-----|
| 137 | The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. <i>British Journal of Haematology</i> , <b>2019</b> , 187, e1-e4  | 4.5  | 2   |
| 136 | Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , <b>2019</b> , 187, 307-318   | 4.5  | 19  |
| 135 | Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. <i>Blood</i> , <b>2019</b> , 134, 35-35 | 2.2  | 30  |
| 134 | Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , <b>2019</b> , 186, 184-188                   | 4.5  | 5   |
| 133 | Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. <i>Blood</i> , <b>2019</b> , 134, 1951-1959   | 2.2  | 19  |
| 132 | Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 961-966   | 4.5  | 6   |
| 131 | A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 606-608   | 4.5  | 5   |
| 130 | Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. <i>Cancer</i> , <b>2019</b> , 125, 559-574                              | 6.4  | 51  |
| 129 | Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. <i>Blood</i> , <b>2019</b> , 133, 1011-1019   | 2.2  | 120 |
| 128 | Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. <i>Leukemia</i> , <b>2018</b> , 32, 2278-2281   | 10.7 | 3   |
| 127 | Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. <i>Blood</i> , <b>2018</b> , 131, 1910-1919   | 2.2  | 267 |
| 126 | Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. <i>Blood</i> , <b>2018</b> , 131, 1820-1832  | 2.2  | 25  |
| 125 | Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. <i>OncImmunology</i> , <b>2018</b> , 7, e1417720   | 7.2  | 7   |
| 124 | Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. <i>Blood</i> , <b>2018</b> , 131, 1704-1711   | 2.2  | 93  |
| 123 | Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 1427-1438   | 1.9  | 4   |
| 122 | Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 504-512                           | 4.5  | 32  |
| 121 | Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4371-4379  | 12.9 | 90  |
| 120 | Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 7502-7502  | 2.2  | 20  |

|     |  |      |     |
|-----|--|------|-----|
| 119 | Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 65-75   | 21.7 | 228 |
| 118 | Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1973-1980   | 2.2  | 174 |
| 117 | A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. <i>Blood</i> , <b>2018</b> , 132, 2249-2259   | 2.2  | 63  |
| 116 | Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. <i>Leukemia</i> , <b>2018</b> , 32, 2388-2398   | 10.7 | 17  |
| 115 | Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 348-356   | 1.9  | 2   |
| 114 | Chronic lymphocytic leukaemia. <i>Nature Reviews Disease Primers</i> , <b>2017</b> , 3, 16096  | 51.1 | 219 |
| 113 | Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 166-174  | 2.2  | 94  |
| 112 | Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. <i>Journal of Immunology</i> , <b>2017</b> , 198, 1740-1747   | 5.3  | 71  |
| 111 | Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. <i>Cancer</i> , <b>2017</b> , 123, 2268-2273  | 6.4  | 83  |
| 110 | NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2017</b> , 15, 293-311  | 7.3  | 49  |
| 109 | Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. <i>British Journal of Haematology</i> , <b>2017</b> , 177, 567-577 | 4.5  | 5   |
| 108 | Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3734-3743   | 12.9 | 82  |
| 107 | Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 826-833   | 2.2  | 442 |
| 106 | B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. <i>Molecular Cancer Research</i> , <b>2017</b> , 15, 1692-1703   | 6.6  | 23  |
| 105 | Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2154-2158   | 12.9 | 43  |
| 104 | PET-positive lymphadenopathy in CLL-Not always Richter transformation. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 405-406   | 7.1  | 6   |
| 103 | A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. <i>Oncotarget</i> , <b>2017</b> , 8, 22104-22112  | 3.3  | 5   |
| 102 | Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. <i>Nature Communications</i> , <b>2016</b> , 7, 11589   | 17.4 | 220 |

|     |   |      |      |
|-----|---|------|------|
| 101 | κ -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. <i>Cancer</i> , <b>2016</b> , 122, 565-73            | 6.4  | 14   |
| 100 | Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 323-32  | 59.2 | 621  |
| 99  | Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 311-22   | 59.2 | 1164 |
| 98  | Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2359-67              | 12.9 | 22   |
| 97  | Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. <i>Blood</i> , <b>2016</b> , 128, 637-637   | 2.2  | 43   |
| 96  | NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2016</b> , 14, 1067-79   | 7.3  | 80   |
| 95  | Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 768-778   | 21.7 | 536  |
| 94  | Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. <i>Blood</i> , <b>2016</b> , 127, 279-86  | 2.2  | 89   |
| 93  | Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. <i>Blood</i> , <b>2016</b> , 127, 303-9   | 2.2  | 347  |
| 92  | Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2015</b> , 15, 385-91                  | 2    | 22   |
| 91  | Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. <i>Haematologica</i> , <b>2015</b> , 100, e311-4   | 6.6  | 12   |
| 90  | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3705-15                                    | 12.9 | 147  |
| 89  | Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. <i>Blood</i> , <b>2015</b> , 125, 2497-506   | 2.2  | 529  |
| 88  | Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 1643-50 | 1.9  | 93   |
| 87  | Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. <i>Blood</i> , <b>2015</b> , 125, 2062-7  | 2.2  | 255  |
| 86  | Updates to the management of chronic lymphocytic leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 662-5   | 7.3  | 4    |
| 85  | Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2015</b> , 13, 326-62  | 7.3  | 37   |
| 84  | Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. <i>Cancer</i> , <b>2015</b> , 121, 3612-21     | 6.4  | 185  |

|    |  |      |      |
|----|--|------|------|
| 83 | Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. <i>Cancer</i> , <b>2015</b> , 121, 3869-76   | 6.4  | 10   |
| 82 | Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , <b>2015</b> , 170, 40-9   | 4.5  | 12   |
| 81 | Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells. <i>Blood</i> , <b>2014</b> , 123, 3780-9   | 2.2  | 16   |
| 80 | Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 48-58          | 21.7 | 372  |
| 79 | Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 1090-9                                   | 21.7 | 283  |
| 78 | Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2014</b> , 14, e105-9      | 2    | 7    |
| 77 | Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. <i>Blood</i> , <b>2014</b> , 123, 3727-32   | 2.2  | 109  |
| 76 | Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , <b>2014</b> , 123, 1424-6  | 2.2  | 15   |
| 75 | Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. <i>Blood</i> , <b>2014</b> , 123, 2783-90  | 2.2  | 97   |
| 74 | Ibrutinib: a paradigm shift in management of CLL. <i>Expert Review of Hematology</i> , <b>2014</b> , 7, 705-17   | 2.8  | 12   |
| 73 | Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. <i>Haematologica</i> , <b>2014</b> , 99, 1350-5   | 6.6  | 55   |
| 72 | Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. <i>Journal of Clinical Pharmacology</i> , <b>2014</b> , 54, 818-27                       | 2.9  | 23   |
| 71 | Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 828-33 | 1.9  | 9    |
| 70 | Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 584-91                            | 2.2  | 127  |
| 69 | Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. <i>Cancer</i> , <b>2013</b> , 119, 3805-11          | 6.4  | 48   |
| 68 | Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 292-5   | 2    | 12   |
| 67 | Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 32-42   | 59.2 | 1656 |
| 66 | Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. <i>Blood</i> , <b>2013</b> , 122, 1891-9   | 2.2  | 157  |

|    |  |      |     |
|----|--|------|-----|
| 65 | Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 488-96                                    | 2.2  | 622 |
| 64 | Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. <i>Blood</i> , <b>2011</b> , 117, 3016-24  | 2.2  | 152 |
| 63 | Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. <i>Blood</i> , <b>2011</b> , 117, 6450-8  | 2.2  | 107 |
| 62 | Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. <i>Blood</i> , <b>2011</b> , 117, 156-64   | 2.2  | 85  |
| 61 | LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients. <i>Blood</i> , <b>2011</b> , 117, 4076-84  | 2.2  | 28  |
| 60 | Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. <i>Blood</i> , <b>2011</b> , 118, 2062-8   | 2.2  | 70  |
| 59 | Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. <i>Blood</i> , <b>2011</b> , 118, 3489-98   | 2.2  | 145 |
| 58 | Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. <i>Blood</i> , <b>2011</b> , 118, 2085-93  | 2.2  | 49  |
| 57 | Non-Hodgkin's lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2011</b> , 9, 484-560   | 4.7  | 47  |
| 56 | Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 4731-41  | 12.9 | 9   |
| 55 | What is the best frontline therapy for patients with CLL and 17p deletion?. <i>Current Hematologic Malignancy Reports</i> , <b>2011</b> , 6, 36-46   | 4.4  | 22  |
| 54 | Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. <i>Cancer</i> , <b>2011</b> , 117, 116-24   | 6.4  | 17  |
| 53 | Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4088-95   | 2.2  | 105 |
| 52 | Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. <i>Blood</i> , <b>2011</b> , 118, 5126-9   | 2.2  | 139 |
| 51 | Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). <i>British Journal of Haematology</i> , <b>2010</b> , 148, 386-93 | 4.5  | 12  |
| 50 | Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL). <i>Journal of Blood Medicine</i> , <b>2010</b> , 1, 115-22   | 2.3  | 1   |
| 49 | Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1749-55  | 2.2  | 483 |
| 48 | Investigational immunotherapeutics for B-cell malignancies. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 884-922  | 2.1  | 21  |



|    |  |     |     |
|----|--|-----|-----|
| 47 | Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression. <i>Modern Pathology</i> , <b>2010</b> , 23, 1518-23   | 9.8 | 19  |
| 46 | Chronic lymphocytic leukemia: new concepts for future therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2010</b> , 10, 369-78   | 2   | 9   |
| 45 | Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. <i>Blood</i> , <b>2010</b> , 115, 489-95   | 2.2 | 75  |
| 44 | Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL. <i>Leukemia Research</i> , <b>2010</b> , 34, 284-8  | 2.7 | 41  |
| 43 | Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2010</b> , 116, 921-921   | 2.2 | 6   |
| 42 | HLA Homozygosity and Haplotype Bias Among Patients with Chronic Lymphocytic Leukemia: Implications for Disease Control by Physiologic Immune Surveillance. <i>Blood</i> , <b>2010</b> , 116, 1370-1370   | 2.2 |     |
| 41 | Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1637-43  | 2.2 | 67  |
| 40 | Chronic lymphocytic leukemia: treatment options for patients with refractory disease. <i>Cancer</i> , <b>2009</b> , 115, 3830-41   | 6.4 | 10  |
| 39 | Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. <i>Blood</i> , <b>2009</b> , 114, 4441-50  | 2.2 | 260 |
| 38 | Isoform-selective phosphoinositide 3Kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. <i>Blood</i> , <b>2009</b> , 113, 5549-57  | 2.2 | 125 |
| 37 | High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. <i>Blood</i> , <b>2009</b> , 113, 3050-8  | 2.2 | 238 |
| 36 | Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. <i>Blood</i> , <b>2009</b> , 113, 3168-71   | 2.2 | 73  |
| 35 | Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. <i>Blood</i> , <b>2009</b> , 113, 4637-45  | 2.2 | 132 |
| 34 | De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. <i>Blood</i> , <b>2009</b> , 114, 957-64  | 2.2 | 134 |
| 33 | Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , <b>2009</b> , 114, 206-206   | 2.2 | 7   |
| 32 | Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial.. <i>Blood</i> , <b>2009</b> , 114, 207-207 | 2.2 | 14  |
| 31 | An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , <b>2009</b> , 114, 883-883   | 2.2 | 12  |
| 30 | Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. <i>Blood</i> , <b>2008</b> , 112, 975-80   | 2.2 | 568 |

|    |   |     |     |
|----|---|-----|-----|
| 29 | Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 196-203                 | 2.2 | 124 |
| 28 | The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. <i>Blood</i> , <b>2008</b> , 112, 711-20   | 2.2 | 85  |
| 27 | Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. <i>Blood</i> , <b>2008</b> , 112, 1923-30  | 2.2 | 254 |
| 26 | Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. <i>Blood</i> , <b>2008</b> , 111, 5291-7  | 2.2 | 355 |
| 25 | Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity. <i>Cancer</i> , <b>2008</b> , 113, 383-7 | 6.4 | 36  |
| 24 | Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. <i>Cancer</i> , <b>2008</b> , 113, 1933-52  | 6.4 | 74  |
| 23 | Lenalidomide as Initial Treatment of Elderly Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , <b>2008</b> , 112, 45-45  | 2.2 | 6   |
| 22 | Chronic Lymphocytic Leukemia: How to Assess Prognosis in 2007. <i>Clinical Leukemia</i> , <b>2007</b> , 1, 162-167  |     | 1   |
| 21 | Gene therapy and active immune therapy of hematologic malignancies. <i>Best Practice and Research in Clinical Haematology</i> , <b>2007</b> , 20, 557-68  | 4.2 | 11  |
| 20 | Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. <i>Blood</i> , <b>2007</b> , 109, 4679-85  | 2.2 | 264 |
| 19 | Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. <i>Blood</i> , <b>2007</b> , 110, 3316-25  | 2.2 | 170 |
| 18 | The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 1931-9   | 1.9 | 85  |
| 17 | Clinical Efficacy of Lenalidomide in Fludarabine-Refractory Chronic Lymphocytic Leukemia Patients.. <i>Blood</i> , <b>2007</b> , 110, 3108-3108   | 2.2 | 7   |
| 16 | New aspects of the treatment of chronic lymphocytic leukemia. <i>Current Hematologic Malignancy Reports</i> , <b>2006</b> , 1, 251-7  | 4.4 |     |
| 15 | Initial therapy for patients with chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , <b>2006</b> , 33, 202-9   | 5.5 | 16  |
| 14 | A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. <i>Cancer</i> , <b>2006</b> , 106, 337-45   | 6.4 | 56  |
| 13 | Current and investigational therapies for patients with CLL. <i>Hematology American Society of Hematology Education Program</i> , <b>2006</b> , 2006, 285-94  | 3.1 | 13  |
| 12 | Genetics and molecular biology of chronic lymphocytic leukemia. <i>Current Treatment Options in Oncology</i> , <b>2005</b> , 6, 215-25  | 5.4 | 12  |

|    |  |     |     |
|----|--|-----|-----|
| 11 | Novel immune-based treatment strategies for chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6325-32  | 2.2 | 46  |
| 10 | Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 4070-8                      | 2.2 | 447 |
| 9  | Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 4079-88 | 2.2 | 811 |
| 8  | Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL.. <i>Blood</i> , <b>2005</b> , 106, 719-719               | 2.2 | 12  |
| 7  | Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. <i>Cancer</i> , <b>2004</b> , 100, 2583-914   | 2.2 | 38  |
| 6  | Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) Is Active for Relapsed and Refractory Patients with CLL.. <i>Blood</i> , <b>2004</b> , 104, 340-340                                      | 2.2 | 11  |
| 5  | Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. <i>Blood</i> , <b>2003</b> , 101, 3413-5  | 2.2 | 220 |
| 4  | High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. <i>Blood</i> , <b>2003</b> , 101, 4903-8               | 2.2 | 121 |
| 3  | Immunologic monitoring in chronic lymphocytic leukemia. <i>Current Oncology Reports</i> , <b>2003</b> , 5, 419-25  | 6.3 | 2   |
| 2  | Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. <i>Cancer</i> , <b>2003</b> , 98, 2657-63  | 6.4 | 186 |
| 1  | CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. <i>Blood</i> , <b>2000</b> , 96, 2917-2924  | 2.2 | 294 |